Table 1. Clinicopathological characteristics of the patients by study group.
| Variables | Breast Cancer | Benign | Normal | ||||
|---|---|---|---|---|---|---|---|
| Premenopausal (N=47) | Menopausal (N=54) | Premenopausal (N=47) | Menopausal (N=54) | Premenopausal (N=47) | Menopausal (N=54) | ||
| Age, median(range) | 40(24-50) | 56(46-78) | 40(26-50) | 56(47-74) | 41(24-53) | 56(46-78) | |
| Family history of breast cancer | 3 | 4 | 1 | 3 | 1 | 2 | |
| History of ovarian cancer | 0 | 0 | 0 | 1 | 0 | 0 | |
| HT history | 0 | 0 | 0 | 0 | 0 | 0 | |
| Prior biopsies | 19 | 22 | 16 | 21 | 0 | 0 | |
| menstrual cycle | |||||||
| week1 | 8 | NA | 8 | NA | 8 | NA | |
| Week2 | 13 | NA | 13 | NA | 13 | NA | |
| Week3 | 13 | NA | 13 | NA | 13 | NA | |
| Week4 | 13 | NA | 13 | NA | 13 | NA | |
| Type | |||||||
| luminal A | 3 | 3 | NA | NA | NA | NA | |
| luminal B | 31 | 34 | NA | NA | NA | NA | |
| HER-2 overexpress | 12 | 12 | NA | NA | NA | NA | |
| basal like | 1 | 5 | NA | NA | NA | NA | |
NA, non-applicable; HER-2, human epidermal growth factor receptor 2, HT hormonal therapy